Chemomab Therapeutics Ltd ADR (CMMB)

$0.84 0.03 (3.33%)

16:00 EDT CMMB Stock Quote Delayed 30 Minutes

CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024

By InvestorPlace Earnings May 9, 2024

Chemomab Therapeutics just reported results for the first quarter of 2024.

CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 57,865

Day's Range $0.83 - $0.88

52-Week Range $0.42 - $1.89

Dividend & Yield N/A (N/A)

CMMB Stock Predictions, Articles, and Chemomab Therapeutics Ltd ADR News

From InvestorPlace
From the Web

Chemomab (CMMB) Stock Gains 30% on FDA Clearance

By David Moadel, InvestorPlace Contributor Feb 21, 2023

Chemomab's regulatory win means the company can take the next step in a clinical trial, so CMMB stock traders are in celebration mode today.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Jun 11, 2021

Good morning, investors! We're kicking off our coverage today with a look at the biggest pre-market stock movers for Friday.

Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Friday Morning

By William White, InvestorPlace Writer Apr 9, 2021

The end of the week is quickly approaching but investors can't relax yet and we're here to help with Friday's biggest pre-market movers.

Chemomab stock jumps on FDA Fast Track tag (NASDAQ:CMMB)

From Seeking Alpha Nov 15, 2023

Chemomab Therapeutics (CMMB) shares jump as FDA grants fast-track designation for its liver disease candidate CM-101. Read more here.

Chemomab Therapeutics files for $200M mixed shelf (NASDAQ:CMMB)

From Seeking Alpha Oct 16, 2023

Chemomab Therapeutics files a prospectus for a mixed shelf offering of up to $200M, but it is not an offer to sell securities.

Chemomab Therapeutics announces key management changes (NASDAQ:CMMB)

From Seeking Alpha Jun 5, 2023

Clinical-stage biotechnology company, Chemomab Therapeutics (CMMB) announces that Adi Mor, PhD, co-Founder and former CEO and current Director and Chief Scientific Officer, has...

CMMB stock jumps as NASH therapy hits main goal in Phase 2 trial (NASDAQ:CMMB)

From Seeking Alpha Jan 3, 2023

Chemomab Therapeutics (CMMB) gained Tuesday pre-market after announcing that its drug for NASH CM-101 reached the main goal in a Phase 2 trial. Read the full story here.

Chemomab Therapeutics names Matthew Frankel as CMO (NASDAQ:CMMB)

From Seeking Alpha Nov 14, 2022

Chemomab Therapeutics (CMMB) announced Monday the appointment of Matthew Frankel, MD, MBA as its new chief medical officer and vice president of drug development. Frankel most...

Chemomab Therapeutics: Q1 Earnings Insights

From Benzinga May 12, 2022

Chemomab Therapeutics (NASDAQ:CMMB) reported its Q1 earnings results on Thursday, May 12, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

ADVERTISEMENT